SCHEMBL6491196

SCHEMBL6491196

COc1ccc(-c2ccc(C(=O)NC3CC4CNC3C4)s2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
ALDH1A1 P00352 1/20 0.55
GLA P06280 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
LMNA P02545 1/20 0.53
MAPK11 Q15759 1/20 0.46
MAPK14 Q16539 1/20 0.46
ESR1 P03372 1/20 0.41
ESRRG P62508 1/20 0.41
ESR2 Q92731 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN11 Q06124 1/20 0.41
ACKR3 P25106 1/20 0.41
HSD17B2 P37059 5/20 0.40
HSD17B1 P14061 3/20 0.40
CHRNA7 P36544 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498904 0.90 HDAC6 (0.50) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL6486663 0.88 ESRRG (0.46) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL6488299 0.87 ESRRG (0.55) MAPK11MAPK14ESR1ESRRGESR2
SCHEMBL6489244 0.86 ESRRG (0.46) KDM4ENPC1ALDH1A1MAPTHPGD
SCHEMBL6498807 0.86 MAPK11 (0.43) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL6497200 0.86 KDM4E (0.51) KDM4ESMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL6497432 0.85 CHRNA7 (0.54) KDM4ESMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL6489478 0.84 KDM4E (0.44) KDM4ESMN1; SMN2NPC1MAPTLMNA
SCHEMBL6495918 0.83 HDAC1 (0.46) KDM4ESMN1; SMN2NPC1ALDH1A1GLA
SCHEMBL6487853 0.82 RXFP1 (0.47) KDM4ESMN1; SMN2NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 KDM4E 2799/4885SMN1; SMN2 1751/4885NPC1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.